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b,c,d Saudi ArabiaBackground: Measurement of N-terminal pro brain natriuretic peptide (NT-proBNP) in the evaluation of patients
with acute coronary syndrome has appeared to be a useful prognostic marker of cardiovascular risk.
Aim of the work: To assess the in-hospital prognostic value of NT-proBNP in patients with acute coronary syn-
drome (ACS) and its relation to the severity of coronary artery disease.
Patients and methods: This study included 132 consecutive patients with ACS, 64 patients with unstable angina
(UA), 46 patients with non-ST segment elevation myocardial infarction (NSTEMI), and 22 patients with ST segment
elevation myocardial infarction (STEMI). ECG, echocardiography and pre and post coronary angiography measure-
ment of troponin I, creatine kinase (Ck), C-reactive protein (CRP) and NT-proBNP were done. Patients were divided
into two groups: Group A with NT-proBNP less than 474 pg/ml and Group B with NT-proBNP equal or more than
474 pg/ml.
Results: There was a significant negative correlation between NT-proBNP and ejection fraction. Incidence of heart
failure and duration of hospital stay were significantly higher in Group B (with NT-proBNP equal or more than
474 pg/ml) than Group A (with NT-proBNP less than 474 pg/ml). Moreover, there was a trend to an increased inci-
dence of cardiogenic shock and mortality in Group B compared to Group A. The number of coronary vessels
affected, severity of stenosis and proximal left anterior descending artery (LAD) disease were higher in Group B
than in Group A. TIMI flow grade was significantly higher in Group A than in Group B.
Conclusion: NT-proBNP is a valuable marker for predicting prognosis and severity of coronary artery disease in
patients with acute coronary syndrome.
 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
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Abbreviations
BMI = body mass index
HTN = hypertension
ACS = acute coronary syndrome
MI = myocardial infarction
UN = unstable angina
STEMI = ST segment elevation myocardial infarction
NSTEMI = non-ST segment elevation myocardial infarction
MACE = major adverse cardiac events
PCI = percutaneous coronary intervention
CABG = coronary artery bypass graft
EF = ejection fraction
NT-proBNP = N-terminal pro brain natriuretic peptide
BNP = brain natriuretic peptide
CRP = C-reactive protein
Ck = creatine kinase
GFR = glomerular filtration rate
LAD = left anterior descending artery
LCX = left circumflex artery
RCA = right coronary artery
M ± SD = mean ± standard deviation
CHF = congestive heart failure
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PREDICTING PROGNOSIS AND SEVERITY OF CORONARY ARTERY DISEASEIntroduction
Natriuretic peptides are vasoactive hormonessecreted by the heart as part of a systemic
response to cardiac stress and ventricular dys-
function. The precursor peptide of brain natri-
uretic peptide (BNP) is stored in granules of
ventricular myocytes, where it is cleaved into an
amino-terminal product (NT-proBNP) and the
physiologically active BNP [1]. Release of BNP
and NT-proBNP are regulated by wall stress and
myocyte stretch [1–3]. Its diverse actions include
natriuresis, vasodilation, inhibition of the renin-
angiotensin-aldosterone system, and inhibition
of sympathetic nerve activity [4]. The BNP levels
trend upward to a peak between 14 and 40 h after
an ischemic event [1,5,6]. Elevated BNP and NT-
proBNP concentrations at admission in the setting
of acute coronary syndrome (ACS) are associated
with poor prognosis, including increased mortal-
ity, development of congestive heart failure
(CHF), and recurrent ischemic events [1,7,8]. Spe-
cifically, when measured between one and four
days after presentation with transmural infarction,
an elevated plasma concentration of BNP was
associated with increased mortality risk, indepen-
dently of left ventricular function [9–11]. Baseline
elevated BNP and NT-proBNP concentrations
were predictive of adverse events at 30 and
90 days. Serial sampling did not improve the prog-
nostic value of BNP or NT-proBNP [12]. Among
patients with suspected ACS considered to be at
low risk because of normal troponin values, NT-
proBNP level of more than 474 pg/ml is able to
identify individuals at higher risk. Because of its
incremental prognostic value, NT-proBNP assess-
ment should be considered in clinical routine for
risk stratification of patients with normal troponin
[13]. NT-proBNP can be a good parameter for
predicting the severity of coronary vessels
involvements alongside other diagnostic tools [14].Aim of this work
The purpose of this study was to assess the
short-term prognostic value of NT-proBNP and
its relation to the severity of coronary artery
disease in patients presenting with acute coronary
syndrome.Methodology
This study was conducted between February
2010 and August 2012 at Jeddah’s King Faisal
Specialist Hospital and Research Centre, Ibn Sina
Faculty of Medicine Hospital, and New JeddahClinic Hospital. It included 132 consecutive
patients presenting with acute coronary syndrome
(ACS), 64 patients with unstable angina (UA), 46
patients with non-ST segment elevation myocar-
dial infarction (NSTEMI), and 22 patients with
ST segment elevation myocardial infarction
(STEMI). A written consent was taken from each
patient according to the declaration of Helsinki
and the ethical committee of all included hospi-
tals. All patients were subjected to full history tak-
ing, clinical examination, ECG, echocardiography
to assess ejection fraction, routine laboratory test-
ing including serum creatinine, serial troponin I,
creatine kinase (Ck), C-reactive protein (CRP)
and NT-proBNP at the time of admission and post
coronary angiography. Serum NT-proBNP was
measured by a double antibody sandwich tech-
nique using Electrochemiluminescence as signal
(Elecsys NT-proBNP, Roche Diagnostics), the
intra-assay coefficient of variation was <6% on
both normal and elevated levels [13]. Coronary
angiography and percutaneous coronary inter-
vention (PCI) when indicated were carried out
for all patients within 48 h of admission.
Our patients were divided into two groups
according to the levels of NT-proBNP: Group A
with NT-proBNP less than 474 pg/ml and Group
B with NT-proBNP equal or more than 474 pg/ml
[13]. Both groups were compared regarding risk
factors, clinical characteristics, major adverse car-
diac events (MACE), ejection fraction and angio-
graphic parameters including: site, degree of
stenosis as assessed quantitatively, number of
lesions, number of vessels affected, LAD versus
non-LAD lesions and proximal versus distal
Table 1. Baseline clinical characteristics of the studied population by NT-proBNP.
Group A (NT pro-BNP < 474 pg/ml
(N = 53)
Group B (NT pro-BNPP 474 pg/ml
(N = 79)
p
Value
Median age (years)
mean ± SD
57.4 ± 9.9 59.8 ± 13.3 >0.05
Male gender (%) 41 (77.4%) 52 (65.8%) >0.05
Obesity (%) 20 (37.7%) 29 (36.7%) >0.05
BMI (mean ± SD) 30.2 ± 5.99 30.4 ± 7.3 >0.05
Diabetes (%) 37 (69.8%) 54 (68.4%) >0.05
HTN (%) 40 (75.5%) 61 (77.2%) >0.05
Smoking (%) 29 (54.7%) 33 (41.8%) >0.05
Hyperlipidemia(%) 49 (92.5%) 68 (86.1%) >0.05
Previous MI (%) 13 (24.5%) 31 (39.2%) >0.05
History of angina (%) 25 (47.2%) 47 (59.5%) >0.05
Previous PCI(%) 15 (28.3%) 20 (25.3%) >0.05
History of CABG (%) 5 (9.4%) 7 (8.9%) >0.05
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was defined by the number of major coronary
arteries with luminal diameter stenosis more than
70% or more than or equal to 50% stenosis in the
left main coronary artery.
Statistical analyses were performed using
Microsoft Office Excel. Continuous variables were
expressed as means and standard deviation and
compared by Student’s t-test while categorical
variables were expressed as percentages andTable 3. Angiographic characteristics of the studied population.
NT pro-BNP < 474 pg/ml (N
LAD (%) 35 (66.03%)
LCX (%) 19 (35.8%)
RCA (%) 22 (41.5%)
Single vessel disease % 14 (26.4%)
Double vessels disease % 22 (41.5%)
Three vessels disease % 9 (16.98%)
Number of vessles mean ± SD 1.68 ± 1.11
Degree of stenosis mean ± SD 81 ± 25.9
Proximal LAD lesions (%) 33 (6.3%)
Distal LAD lesions (%) 6 (11.3%)
TIMI flow mean ± SD 1.14 ± 0.95
Thrombus % 8 (15.1%)
Table 2. ECG, Echocardiographic and laboratory characteristics of
% of patients who developed ST segment deviation at time of ad
T wave changes %
EF % (mean ± SD)
CRP (mg/dl) (mean ± SD)
Troponin pre angio. (mean ± SD)
Troponin post angio. (ng/ml) (mean ± SD)
CK pre angio (ng/ml) (mean ± SD)
CK post angio. (ng/ml) (mean ± SD)
Serum creatinin (mmol/l) (mean ± SD)
GFR (mean ± SD)compared by chi square test, and results were
considered significant if the P value was <0.05.Results
There were no significant differences between
Group A (NT-proBNP less than 474 pg/ml) and
Group B (NT-proBNP equal or more than
474 pg/ml) regarding the base line characteristics
(Table 1).= 53) NT pro-BNPP 474 pg/ml (N = 79) p Value
65 (82.28.5%) <0.05
39 (49.4%) >0.05
46 (58.2%) >0.05
20 (25.3%) >0.05
27 (34.2%) >0.05
25 (31.6%) >0.05
1.95 ± 1.07 0.004
89.1 ± 18.7 0.039
54 (68.4%) 0.001
5 (6.3%) >0.05
0.82 ± 0.8 0.039
9 (11.4%) >0.05
the studied population.
NT pro-BNP < 474
pg/ml (N = 53)
NT pro-NPP 474
pg/ml (N = 79)
p Value
mission. 20 (37.7%) 35 (44.3%) >0.05
20 (37.7%) 54 (68.4%) <0.05
45.7 ± 7.8 36.7 ± 11.6 0.006
18.5 ± 34.1 16.9 ± 34.0 0.79
0.9 ± 3.2 6.4 ± 28.6 0.166
1.34 ± 3.3 8.8 ± 48.7 0.268
363.3 ± 815.9 243.6 ± 504.4 0.3
335 ± 478.3 311.1 ± 515.8 0.639
101.7 ± 68.7 128.3 ± 119.9 0.146
56.1 ± 9.7 53.0 ± 15.0 0.186
Table 4. Prognostic characteristics of the studied population.
NT pro-BNP less than 474 pg/ml (N = 53) NT pro-BNP equal or more than 474 pg/ml (N = 79) p Value
Heart failure 2 (3.8%) 12 (16.2%) 0.03
Cardiogenic shock 1 (1.9%) 6 (7.6%) 0.05
Mortality (%) 0 (0%) 4 (5.06%) 0.06
Duration of hospital stay 4.1 ± 2.3 7.1 ± 4.5 0.005
Table 5. Diagram for correlation between NT-pro BNP and ejection fraction.
EF less than 40%N. 42 EF 40–50 N. 70 EF more than50 N. 20 P1 P2 P3
NT pro-BNP 2569.5 ± 2270.5 1342.46 ± 2002.0 328.4 ± 46.8 0.001 0.02 0.05
Abbreviations: P1 = EF less than 40% vs. EF 40–50%. P2 = EF less than 40% vs. EF more than 50%. P3 = EF40–50% vs, EF more than 50%.
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PREDICTING PROGNOSIS AND SEVERITY OF CORONARY ARTERY DISEASEThere were no significant differences between
Group A and Group B regarding ST segment devi-
ation, CRP, troponin I and Ck (pre and post coro-
nary angiography), serum creatinine and
glomerular filtration rate. However, there were
significant reductions in the ejection fraction and
significant increase in T wave changes in Group
B compared to Group A (Table 2).
We found that the number of vessels affected
and the percentage of stenosis were higher in
Group B compared to Group A. Also, the percent-
age of proximal LAD stenosis was significantly
higher in Group B compared to Group A. The
TIMI flow was found to be significantly higher in
Group A compared to Group B (Table 3).
There were significant increases in the incidence
of heart failure and duration of hospital stay in
Group B compared to Group A. There was a trend
of increased incidence of cardiogenic shock and
mortality in Group B compared to Group A, but
this did not reach a significant value (Table 4).0 
1000
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NT pro BNP
Figure 1. Mean and SD of NT-pro BNP according to the ejection
fraction of all patients.When we classified patients according to their
ejection fraction (EF) into three subgroups (less
than 40%, from 40% to 50%, and more than 50%)
we found that NT-proBNP levels were signifi-
cantly higher in patients with EF less than 40%
than other subgroups with EF from 40% to 50%,
and more than 50% (Table 5; Fig. 1).
Patients with STEMI were found to have signif-
icantly higher levels of CRP, troponin I, NT-proB-
NP and CK compared to patients with NSTEMI
and UA. Also, patients with NSTEMI were found
to have significantly higher levels of CRP, tropo-
nin I, NT-proBNP and CK compared to patients
with UA. Patients with STEMI were found to have
significantly lower EF compared to patients with
NSTEMI and UA (Table 6).Discussion
Brain natriuretic peptide is a neurohormone syn-
thesized in ventricular myocardium and released
in response to cardiac stretch. NT-proBNP is the
N-terminal fragment of the prohormone BNP.
These natriuretic peptides have prognostic value
across the full spectrum of acute coronary syn-
drome patients. Patients with elevated BNP or
NT-proBNP are at significantly increased risk for
subsequently developing heart failure and death,
in both short and long-term outcomes. This is seen
regardless of their troponin levels and even when
there is no clinical evidence of heart failure
[15,16]. The prognostic value of these peptides is
over conventional risk factors like age, Killip class,
and left ventricular ejection fraction. Studies have
shown that BNP can predict high risk features in
ACS, such as more severe underlying atheroscle-
rosis, left ventricular dysfunction, left ventricular
hypertrophy, and the burden of the ischemic insult
[17]. In patients with ACS, the higher the BNP, the
more severe the hemodynamic insult due to ische-
mia and the worse the prognosis [18].
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Table 6. Comparison between the different presentation of ACS regarding heart failure, EF and laboratory results.
STEMI N = 22 NSTEMI N = 46 UA N = 64 P1 P2 P3
EF % 36.8 ± 7.9 38.9 ± 11.1 44.5 ± 11.8 0.006 0.04 0.01
NTpro-BNP pre angio. M ± SD 2295 ± 3215 1686.7 ± 1595.9 1317.7 ± 1891.7 0.001 0.018 0.284
NTpro-BNP post angio. M ± SD 3760.1 ± 3583.1 2410. 2 ± 374 1460.4 ± 2067 0.004 0.028 0.69
CRP M ± SD 39.8 ± 45.9 19.8 ± 30.3 8.3 ± 7.5 0.036 0.004 0.001
Troponin pre angio. M ± SD 8.01 ± 15.4 7.97 ± 26.0 0.20 ± 1.25 0.99 0.005 0.019
Troponin post angio. M ± SD 31.8 ± 89.2 1.1 ± 1.2 0.11 ± 0.32 0.022 0.005 0.001
CK pre angio. M ± SD 1140 ± 1281 183.4 ± 151.8 77.8 ± 45.8 0.003 0.002 0.001
CK post angio. M ± SD 891.9 ± 699 318.8 ± 358 125.8 ± 365.4 0.002 0.004 0.007
P1 = STENI vs. NSTEMI. P2 = STEMI vs. UA. P3 NSTEMI vs. UA.
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fraction was significantly reduced in patients with
NT-proBNP equal to or more than 474 pg/ml com-
pared to patients with NT-proBNP less than
474 pg/ml. This result was comparable to that
reported by Shahabi et al. [14]. Furthermore, we
found highly significant negative correlation
between NT-proBNP and ejection fraction
(r = 0.234, p = 0.0063). This result was concordant
with Shahabi et al. [14] and was also supported
by Emdin et al. [19] who found that NT-proBNP
had acceptable accuracy for identifying heart fail-
ure due to left ventricular dysfunction [19]. Addi-
tionally, in the Grewal study, BNP was identified
as the strongest predictor of diastolic dysfunction
as determined by Doppler-echocardiography [20].
We found that in patients with acute coronary
syndrome, the number of vessels affected and
percentage of stenosis were significantly higher
statistically in those with high NT-proBNP (equal
to or more than 474 pg/ml) compared to those
with low NT-proBNP (less than 474 pg/ml). These
results were concordant with other studies that
focused on the association between the severity
of CAD and NT-pro-BNP level [21–23]. Weber
et al. [21] found that serum BNP level could effec-
tively predict coronary involvement based on the
number of affected coronary vessels in patients
with angina pectoris. Palazzuoli et al. [22] found
that BNP was associated with a larger extent and
greater severity of myocardial ischemia in
patients with non-ST segment elevation myocar-
dial infarction. Also, Sadanandan et al. [23]
showed that patients with BNP more than 80 pg/
ml had tighter culprit vessel stenosis and a higher
number of culprit vessels compared to cases with
lower plasma BNP level. Furthermore, Ham-
ishayev et al. [24] found a significant correlation
between NT-proBNP levels and the number of
affected vessels in patients with unstable angina
and ST segment elevation MI [24]. Also, Niizuma
et al. found that plasma B-type natriuretic peptide
levels reflect the presence and severity of stablecoronary artery disease in chronic hemodialysis
patients [25].
In contrast, in a logistic regression analysis by
Nishikimi et al. it was revealed that N-terminal
pro ANP, but not BNP, was independently associ-
ated with coronary artery stenosis after adjusting
for clinical and demographic variables. However,
the sensitivity, specificity, and positive and nega-
tive predictive values of each peptide were not
sufficiently high to be used for prediction. In their
study, patients with no evidence of CAD were
compared to those with CAD, and the severity of
coronary defects was not quantitatively deter-
mined [26].
In our study, we found that patients with ele-
vated NT-proBNP more than 474 pc/ml had a sig-
nificantly lower TIMI flow grade compared to
patients with NT-proBNP less than 474 pc/ml.
This result was concordant with Mega et al. [27]
who found that elevated BNP at presentation
was associated with evidence of subsequent
impaired epicardial and myocardial reperfusion.
Specifically, patients with BNP more than 80 pg/
ml were more likely to have incomplete reperfu-
sion of the infarct-related artery. In addition, ele-
vated BNP was associated with incomplete (less
than 70%) resolution of ST-segment elevation,
which is an indicator of impaired myocardial tis-
sue-level reperfusion [28].
In our study, we found a significantly higher
incidence of heart failure and longer duration of
hospital stay among patients with high NT-proB-
NP compared to those with low NT-proBNP. Also,
there was a trend toward higher incidence of car-
diogenic shock and mortality among patients with
high NT-proBNP.
Patients with higher BNP had an 11-fold higher
risk of death compared to those with lower BNP. A
trend toward more frequent new or worsening
CHF was also apparent among those with BNP
more than 80 pg/ml [27]. These results were con-
sistent with many studies of patients with STEMI
[1,5,9–11,29]. Together, these studies provide con-
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PREDICTING PROGNOSIS AND SEVERITY OF CORONARY ARTERY DISEASEsistent evidence for the additive prognostic value
of BNP. Moreover, whether measured at presenta-
tion or later during recovery, BNP is one of the
most robust indicators of mortality risk [27]. This
strong prognostic association in STEMI parallels
that among patients with non-ST segment eleva-
tion acute coronary syndromes [30].Conclusion
In general, according to the results of this study
and previous similar studies, it seems that the
NT-proBNP in acute coronary syndrome is an
appropriate marker associated with more coronary
artery involvements regarding number of vessels
affected and severity of stenosis. In addition, it is
a valuable marker for predicting higher incidence
of heart failure and lower ejection fraction.Limitations of the study
(1) The number of patients in this study was rel-
atively small and the duration of follow-up was
short (hospital stay only) so mortality and cardio-
genic shock did not reach statistical significance.
(2) The study excluded patients with hepatitis C
but did not exclude patients with mixed cryoglob-
ulinemia where many studies revealed high levels
of circulating NT-proBNP in patients with mixed
cryoglobulinemia and hepatitis C. Antonelli et al.
[31] however, concluded that increase in NT-proB-
NP could indicate the presence of a subclinical
cardiac dysfunction.Recommendations
Measurements of the NT-proBNP in patients
with acute coronary syndrome is a useful marker
for risk stratification of these patients.
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